INmune Bio Inc.
INMB
$2.17
$0.094.33%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 50.00K | 50.00K | 50.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 0.00 | 0.00 | 50.00K | 50.00K | 50.00K |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 0.00 | 0.00 | 50.00K | 50.00K | 50.00K |
| SG&A Expenses | 10.05M | 10.02M | 10.17M | 9.24M | 8.82M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 20.20M | 26.78M | 30.92M | 34.91M | 39.77M |
| Operating Income | -20.20M | -26.78M | -30.87M | -34.86M | -39.72M |
| Income Before Tax | -18.42M | -41.60M | -45.93M | -49.89M | -55.51M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -18.42 | -41.60 | -45.93 | -49.89 | -55.51 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -18.42M | -41.60M | -45.93M | -49.89M | -55.51M |
| EBIT | -20.20M | -26.78M | -30.87M | -34.86M | -39.72M |
| EBITDA | -20.01M | -18.60M | -12.84M | -7.42M | -- |
| EPS Basic | -0.69 | -1.69 | -1.92 | -2.14 | -2.50 |
| Normalized Basic EPS | -0.45 | -0.63 | -0.77 | -0.91 | -1.12 |
| EPS Diluted | -0.69 | -1.69 | -1.92 | -2.14 | -2.50 |
| Normalized Diluted EPS | -0.45 | -0.63 | -0.77 | -0.91 | -1.12 |
| Average Basic Shares Outstanding | 106.49M | 103.07M | 98.99M | 94.63M | 88.23M |
| Average Diluted Shares Outstanding | 106.49M | 103.07M | 98.99M | 94.63M | 88.23M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |